Fig. 2
Patient attrition. aJanuary 1, 2018 to December 31, 2019. bThe index date was defined as the first medical or pharmacy claim for vedolizumab or ustekinumab during the patient identification period. cRheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, or noninfectious uveitis.dOther advanced therapies approved for the treatment of Crohn’s disease or ulcerative colitis